Neurotech International

Neurotech is a clinical-stage biopharmaceutical development company focused on paediatric neurological disorders.

[Neurotech International @NeurotechInt]

First child dosed in Neurotech's Phase 3 cannabis trial for autism | $NTI Media coverage by @AusBiotech.
https://t.co/EXJKD7Ee2t

[Neurotech International @NeurotechInt]

Our Quarterly Activities Report for the period ending 30 September 2026 has been released.

View the full report: https://t.co/pGs5GBMWUF

[Neurotech International @NeurotechInt]

Rett Syndrome Awareness Month is about more than understanding the condition. It is also an opportunity to recognise the people and families behind every diagnosis and the importance of continuing to advance research.

For Neurotech, that means continuing our work to investigate NTI164 across paediatric neurological disorders where there remains a need for new treatment options.

Our Phase I/II Rett syndrome study has provided important clinical evidence for NTI164, with statistically significant and clinically meaningful results reported from the trial.

As Rett Syndrome Awareness Month comes to a close, we recognise the Rett community and the families, clinicians, researchers and advocates whose participation and commitment make clinical research possible.

#RettSyndromeAwarenessMonth #RettSyndrome #RettAwareness #Neurotech #NTI164 #RareDisease #ClinicalResearch #PaediatricNeurology

[Neurotech International @NeurotechInt]

Investor Presentation: October 2026
15th Annual Australian Microcap Investment Conference, Melbourne
View the full $NTI Presentation here: https://t.co/OuZzinjUlL
#Neurotech #NTI164 #ASX #MicrocapConference #Biotechnology

[Neurotech International @NeurotechInt]

We’re looking forward to participating in the 15th Annual Australian Microcap Investment Conference, taking place at the Sofitel Melbourne on Collins on 20–21 October 2026.

Executive Chairman Mark Davies will present on Tuesday, 20 October at 2:45pm, providing investors with an update on NTI’s progress, including the pivotal Phase 3 Beyond Harmony clinical trial evaluating NTI164 in children with autism spectrum disorder.

We look forward to connecting with investors and sharing more about Neurotech’s clinical development program and the pathway towards potential regulatory registration and commercialisation of NTI164.

Event: 15th Annual Australian Microcap Investment Conference
Date: Tuesday, 20 October 2026
Time: 2:45pm
Venue: Sofitel Melbourne on Collins, Melbourne

For more information about the conference:

https://t.co/XdaVDPmPBu

$NTI #Neurotech #NTI164 #ASX #MicrocapConference #Biotechnology #ClinicalResearch

[Neurotech International @NeurotechInt]

Health Check: Neurotech shares surge on upbeat research report | $NTI Media coverage by @Stockhead
https://t.co/BGpfJ2b6CV

[Kristin Rowe @MsKrowe1376]

Canary Capital has initiated coverage on @NeurotechInt (#ASX: $NTI) with a Strong Buy recommendation and an intrinsic value estimate of $0.155 per share. Based on the share price of $0.013 used in the report, this represents potential upside of approximately 812%.

A key takeaway from the report is NTI's progress towards a potentially significant clinical milestone, with its Beyond Harmony Phase III trial now underway. The 200-patient study is evaluating NTI164 for #Autism Spectrum Disorder (#ASD), following positive Phase II/III results that demonstrated improvements in overall illness severity, adaptive functioning and social responsiveness.

Canary Capital also highlights the commercial opportunity for NTI164, particularly in Australia, where the company intends to pursue initial commercialisation before exploring licensing opportunities in larger international markets.

Canary's valuation is based solely on the Australian ASD opportunity and does not include potential value from Neurotech's other programs in Rett syndrome, PANS/PANDAS and cerebral palsy, or from international markets.

While clinical and regulatory risks remain, Canary Capital identifies the Phase III trial results as a key catalyst for the company's future valuation.

#Healthcare #AutismResearch #Neuroinflammation

[Neurotech International @NeurotechInt]

As we continue to recognise Rett Syndrome Awareness Month, we’re highlighting the clinical research Neurotech has undertaken with NTI164 in Rett syndrome.

Our Phase I/II Rett syndrome clinical trial evaluated daily oral treatment with NTI164 in 14 patients with Rett syndrome.

At 12 weeks, 93% of patients showed improvement across four core Rett anchors measured by Clinical Global Impression - Improvement, with 36% rated “very much/much improved”. The Rett Syndrome Behavioural Questionnaire also showed a statistically significant improvement compared with baseline.

These results form part of Neurotech’s growing body of clinical evidence for NTI164 across paediatric neurological disorders.

#RettSyndromeAwarenessMonth #RettSyndrome #Neurotech #NTI164 #ClinicalTrials #ClinicalResearch #RareDisease #Biotechnology

[Neurotech International @NeurotechInt]

Understanding Rett syndrome starts with understanding what causes it. Rett syndrome is a rare genetic neurodevelopmental disorder most commonly caused by a spontaneous pathogenic variant in the MECP2 gene, which plays an important role in brain development and the regulation of other gene functions.

For children and families living with Rett syndrome, the condition can affect communication, movement and many other aspects of everyday life.

Neurotech’s work with NTI164 is focused on paediatric neurological disorders associated with neuroinflammation. Our Phase I/II Rett syndrome clinical trial investigated the effects of daily oral treatment with NTI164 over 16 weeks.

This Rett Syndrome Awareness Month, we recognise the families, clinicians, researchers and advocates working to improve understanding and advance new treatment options.

#RettSyndromeAwarenessMonth #RettSyndrome #KnowRett #Neurotech #NTI164 #RareDisease #PaediatricNeurology $NTI

[Neurotech International @NeurotechInt]

October is Rett Syndrome Awareness Month which an opportunity to raise awareness and understanding of this rare neurodevelopmental disorder and the children and families living with it.

Rett syndrome can affect almost every aspect of an individual’s life, including their ability to speak, walk, eat and breathe, with symptoms often beginning in early childhood.

At Neurotech, Rett syndrome is an important part of our clinical development program for NTI164. Our Phase I/II clinical trial evaluated NTI164 in 14 patients with Rett syndrome, contributing to our broader work to develop new treatment options for paediatric neurological disorders.

Throughout October, we’ll be sharing more about Rett syndrome, our clinical research and the results observed with NTI164.

#RettSyndromeAwarenessMonth #RettSyndrome #RettAwareness #Neurotech #NTI164 #ClinicalResearch #RareDisease $NTI

[Neurotech International @NeurotechInt]

Executive Chairman Mark Davies recently joined Scott Haywood on Money News to discuss NTI164 and our clinical development program in autism.

Mark discussed the results from Neurotech’s previous 54-patient autism study and the recent commencement of the pivotal Phase 3 Beyond Harmony trial, which is planned to enrol up to 200 patients. He also spoke about the pathway towards potential TGA registration and $NTI’s broader strategy for NTI164.

Listen to the full interview with Mark below.
https://t.co/7iykYloHGm @brookecorte

#Neurotech #NTI164 #BeyondHarmony #Autism #ASD #Phase3 #ClinicalResearch #Biotechnology #ASX

[Neurotech International @NeurotechInt]

We’ve dosed the first patient in our pivotal Phase 3 Beyond Harmony clinical study of NTI164 in Autism Spectrum Disorder, marking a significant milestone for Neurotech.

All sites have now been initiated for the national multi-centre, randomised, double-blind, placebo-controlled study, designed to evaluate the efficacy, safety and tolerability of NTI164 in children with ASD.

Up to 200 patients are planned for enrolment under Beyond Harmony’s adaptive trial design, with six sites across Australia.

Beyond Harmony builds on the clinical evidence generated from Neurotech’s earlier HARMONY Phase II/III study, which demonstrated clinically meaningful and statistically significant benefits across multiple validated measures, together with an excellent safety profile.

Our focus is on successfully executing Beyond Harmony and progressing NTI164 toward regulatory registration as a new treatment option for children with ASD.

Read the full $NTI #ASX Announcement here: https://t.co/xOU683QNMa

#Neurotech #NTI164 #BeyondHarmony #Autism #ASD #Phase3 #ClinicalStudy #ClinicalDevelopment

[Neurotech International @NeurotechInt]

Mark Davies, Executive Chairman of Neurotech International Ltd, presented to investors at the @NWRcomms investor event last week.

Mark provided an update on Neurotech’s recent progress, the continued development of NTI164 and the Company’s clinical and commercialisation strategy.

Thank you to everyone who joined us and took the opportunity to hear more about $NTI and our work in paediatric neurological disorders.

#Neurotech #NTI164 #Biotechnology #ClinicalResearch #NeurodevelopmentalDisorders #ASX

[Neurotech International @NeurotechInt]

“It’s changed every aspect of life.” In this clip from A Current Affair, Libby Harper and her son Tate share their experience following Tate’s participation in Neurotech’s NTI164 clinical trial.

Tate talks about being able to stay at school for the whole day, while Libby reflects on the everyday changes that have made such a difference to their family; from getting through the morning to completing four days of school in a row. For Libby, the most significant part has been seeing that progress continue.

Thank you to Libby and Tate for sharing their story and helping bring greater awareness to the experiences of families living with autism spectrum disorder.

Watch the full $NTI episode here: https://t.co/Byc6qLfWLP

#Neurotech #NTI #NTI164 #Autism #ASD #ClinicalResearch #NeurodevelopmentalDisorders #PaediatricHealth #Biotechnology @Ninecomau @ACurrentAffair9

[Neurotech International @NeurotechInt]

We were honoured to see #NTI164 featured on @ACurrentAffair9 in a story highlighting the hope that clinical research is bringing to families living with #autism spectrum disorder.

The segment followed Libby Harper and her son Tate, sharing their journey from the challenges they faced before the Harmony Study to the changes Libby has observed since Tate participated in the clinical trial.

The story also shared the experiences of Bel and her son Brody, providing another family's perspective on the challenges of autism and the search for treatment options that can make a meaningful difference.

It also featured Professor Michael Fahey, Paediatric Neurologist and Neurogeneticist at Monash Children's Hospital and Principal Investigator of the #NTI164 clinical trials, who discussed the importance of rigorous clinical research and the development of NTI164 for children with neurodevelopmental disorders.

Thank you to Libby and Tate, Bel and Brody, for generously sharing their families' stories and helping raise awareness of the need for continued research into new treatment options for children with autism spectrum disorder.

Watch the full A Current Affair story below.
https://t.co/z1ECpy3J3b

$NTI #NTI164 #Autism #ASD #NeurodevelopmentalDisorders #ClinicalResearch @Channel9 @9Now

[Neurotech International @NeurotechInt]

We've appointed Mark Davies as Executive Chairman. As Executive Chairman, Mr Davies will assume a more active role in the strategic and operational leadership of Neurotech, including corporate strategy, capital markets and funding initiatives, partnering and licensing activities, investor engagement, governance, and strategic oversight of the Company's clinical and regulatory programs.

The appointment reflects Neurotech's progression into its next stage of development, with an increased focus on the Phase III program, funding strategy and potential partnering and licensing opportunities.

Read the full $NTI #ASX Announcement here: https://t.co/Y8X8nKqirF

[Neurotech International @NeurotechInt]

Our MD & CEO, Dr Anthony Filippis, has been actively promoting @NeurotechInt recently at various industry & investor events.

Last week, he attended the 20th BioShares Biotech Summit 2026 in New Zealand, alongside a range of biotech-focused market participants.

He also recently presented at the TechKnow Invest Roadshow in Melbourne, sharing an update on Neurotech’s continued progress. Anthony highlighted the advancement of NTI164, our Phase 3 clinical program, along with key milestones supporting our global development and commercialisation strategy.

📽️A recording of the presentation is now available. Click below to watch. https://t.co/KprrQRUbKL

[Neurotech International @NeurotechInt]

We’re received strong investor support, securing approximately $4.5 million (before costs) through a placement of new fully paid ordinary shares. The Placement was backed by both existing and new institutional and sophisticated investors, with funds raised to primarily support the Company’s Phase III double-blind, placebo-controlled clinical trial of NTI164 in children with Autism Spectrum Disorder (ASD).

This support marks an important step forward as Neurotech continues to advance its clinical development program and work towards delivering potential new treatment options for children with ASD.

Neurotech’s Managing Director and CEO, Dr Anthony Filippis, said:
"We are pleased to have secured support from new and existing shareholders, enabling Neurotech to progress NTI164 through its Phase 3 clinical program. This capital raising provides the Company with the cash runway to deliver the next major value inflection point for NTI164."

Read the full ASX release here: https://t.co/nNjinPMHIU

#NTI #Neurotech #NTI164 #Autism #ASD #Neurotherapeutics #ClinicalResearch #Biotech #PaediatricNeurology #ClinicalDevelopment #NeurodevelopmentalDisorders

[Neurotech International @NeurotechInt]

We're pleased to share our report for the quarter ending 30 June 2026: https://t.co/57tlMznuSo

During the period, our activities were focused on execution of the NTI164 development strategy, with workstreams spanning clinical operations, regulatory preparation, scientific validation and partnering engagement across our paediatric neurological disorder pipeline. $NTI

[Neurotech International @NeurotechInt]

We've reached another important external validation of NTI164, with our Phase II/III autism data accepted for publication in the peer-reviewed journal Neurotherapeutics, the official journal of the American Society for Experimental Neurotherapeutics.

The publication strengthens the evidence base for NTI164 and adds to a growing body of peer-reviewed data spanning multiple paediatric neurological indications, supporting the clinical outcomes and mechanistic rationale for NTI164.

Read the full $NTI ASX Announcement here: https://t.co/LnhUvY6SGK

#Autism #ASD #Neurotherapeutics #Biotech #PaediatricNeurology